Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Vistagen eyes FDA path after signal in very severe SAD

Aug 14, 2026, 8:41 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive signal in a very severe SAD subgroup could unlock a registrational pathway if FDA feedback is favorable; cash runway and leadership appointments reduce downside risk, though the overall Phase 3 miss tempers upside.

AI summary

What happened, with direct paths to the underlying reporting

Vistagen reported fiscal Q1 2027 results highlighting a nominal signal in very severe social anxiety from PALISADE-4, while the overall Phase 3 failed to meet its primary endpoint. The company plans FDA discussions on a potential registrational pathway for fasedienol, adds experienced leadership, and maintains a cash runway into 2027 with $31.7 million on hand while weighing strategic options and cost discipline.

PALISADE-4 subpopulation shows nominal improvement; overall endpoint missed.
OLE PALISADE-3 indicates tolerability; exploratory efficacy improves over 4 months.
FDA engagement planned this quarter on potential registrational path for fasedienol.
Cash runway into 2027; cash/marketable securities at $31.7M; Fuji revenue $1.2M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Vistagen eyes FDA path after signal in very severe SAD

Vistagen Reassesses SA Strategy After Post-Hoc Signal and FDA Pathway Talks

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study